| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/04/2003 | US20030166874 Induce fibrin deposits in tumor; antitumor agents |
| 09/04/2003 | US20030166873 Endothelial growth factor; measuring binding to monoclonal antibodies; calibration |
| 09/04/2003 | US20030166870 Detection sensitivity to virus; administering binding antibody; measurement; calibration; viricides |
| 09/04/2003 | US20030166867 Fibrin nanoparticles and uses thereof |
| 09/04/2003 | US20030166863 Macrophage migration inhibitory factor-3 |
| 09/04/2003 | US20030166862 Purified mammalian CTLA-8 antigens and related reagents |
| 09/04/2003 | US20030166859 Controlling cell proliferation, cell differentiation; anticancer agents |
| 09/04/2003 | US20030166857 Genes for receptor tyrosine kinases and their cognate ligands, their insertion into genetic engineered DNA vectors; useful in the diagnosis and treatment of neoplastic diseases |
| 09/04/2003 | US20030166856 A set of open reading frames encoded with the template as the plus strand of the proviral DNA, and located in the region of HIV-1 long terminal repeat, and the genes encode a set of antisense proteins |
| 09/04/2003 | US20030166854 Allelic variant of human STAT3 |
| 09/04/2003 | US20030166853 Mucin peptide with immunoenhancing properties |
| 09/04/2003 | US20030166850 Containing an isolated human evectin polypeptide binding domain |
| 09/04/2003 | US20030166849 A peptide of at least 5 amino acids containing a unique portion of a semaphorin, and such peptide has a semaphorin binding specificity |
| 09/04/2003 | US20030166848 Polypeptides having specific amino acid sequence lacking its associated signal peptide; a chimeric polypeptide fused to a heterologous polypeptide which is an epitope tag or an Fc region of an immunoglobulin |
| 09/04/2003 | US20030166847 Novel human leptin receptor gene-related protein |
| 09/04/2003 | US20030166846 Self-aligning peptides modeled on human elastin and other fibrous proteins |
| 09/04/2003 | US20030166845 Novel proteins and nucleic acids encoding same |
| 09/04/2003 | US20030166843 Scalable three dimensional set of points is derived from structure coordinates of at least the backbone atoms of amino acids representing FAD binding site and/or an NADPH binding site of an staphylococcus thioredoxin reductase molcule |
| 09/04/2003 | US20030166838 A biologically active peptide at least 85% identical to a peptide: (a) X01ValSerGluX02GlnLeuX03HisX04X05GlyLysX06; (b) fragments containing amino acids 1-9, 1-10, 1-11, 1-12,(c) a salt or (d) N- or C- derivatives |
| 09/04/2003 | US20030166837 Isolated molecules which complex with HLA-Cw*16 molecules, and uses thereof |
| 09/04/2003 | US20030166836 A polypeptide produced by the parathyroid glands using such analogues alone or in combination with a bisphosphonate or calcitonin to treat osteoporosis |
| 09/04/2003 | US20030166835 Dehydroalanine-containing lantibiotic |
| 09/04/2003 | US20030166832 Methods and compositions for impairing multiplication of HIV-1 |
| 09/04/2003 | US20030166662 Administering a selective cyclic guanosine monophosphate (cGMP) phosphodiesterase 5 (PDE5) inhibitor, e.g. Rezulin, Avandia, Actos; hypotensive, antidiabetic and hypoglycemic agents; gout; anticoagulants; atherosclerosis; obesity |
| 09/04/2003 | US20030166604 Modulating transcription of genes in vascular cells |
| 09/04/2003 | US20030166603 Using a p53- expressing viral vector as anticarcinogenic agents |
| 09/04/2003 | US20030166601 Drug delivery of the nucleic acid into a target tissue or cell, comprising a core complex contains a nucleic acid and complex forming agents, fusion with cell membranes with nuclear uptake; polymeric outer shell |
| 09/04/2003 | US20030166599 Uses of tgap7 for the modulation of leucocyte activation |
| 09/04/2003 | US20030166591 Testosterone-repressed prostate message-2 (TRPM-2); gene expression inhibition; increased antitumor activity |
| 09/04/2003 | US20030166590 Microsomal triglyceride transfer protein |
| 09/04/2003 | US20030166589 Method and pharmaceutical composition for the treatment of multiple sclerosis |
| 09/04/2003 | US20030166588 Splice-region antisense composition and method |
| 09/04/2003 | US20030166587 Compounds and methods for modulating activation of NF-kB |
| 09/04/2003 | US20030166586 C/EBP beta isoforms and methods of use in cell regulation and anti-tumorigenesis |
| 09/04/2003 | US20030166580 Substituted amino carboxamides for the treatment of alzheimer's disease |
| 09/04/2003 | US20030166579 Thrombin inhibitors comprising an aminoisoquinoline group |
| 09/04/2003 | US20030166578 Combinations od dipeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabetes mellitus |
| 09/04/2003 | US20030166577 Inhibitors for the blood-clotting factor xa |
| 09/04/2003 | US20030166576 Urokinase inhibitors |
| 09/04/2003 | US20030166575 Such as N-(toluene-4-sulfonyl)-(2S-indolin-2-carbonyl)-L-phenylalanine; integrins, cd antigens (VLA-4); antiinflammatory agents |
| 09/04/2003 | US20030166574 1,3,4-Oxadiazoline derivatives and drugs containing these derivatives as active ingredient |
| 09/04/2003 | US20030166573 Such as (2S)-N-((2S)-4-methyl-1-(5-(1-methylethylthio)1,3,4-oxadiazol-2-yl)-1-oxo-2 -pentyl)-2-benzyloxycarbonylamino-4-methylpentanamide for inhibition of cysteine proteases; antiinflammatory agents |
| 09/04/2003 | US20030166572 2-Amino-3-hydroxy-4-tert-leucyl-amino-5 phenyl-pentanoic acid amide derivatives |
| 09/04/2003 | US20030166571 Comprises hexapeptides as agonists/antagonists when exposed to human ORL-1 (orphan) receptors; anxiolytics, diuretics, anticancer agents |
| 09/04/2003 | US20030166569 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 09/04/2003 | US20030166567 Anti-aging and wound healing compounds |
| 09/04/2003 | US20030166566 Modified with water-soluble polyoxyethylene glycol |
| 09/04/2003 | US20030166565 CD antigens; for regulating inflammation; nuclear magnetic resonance; drug screening |
| 09/04/2003 | US20030166564 Reducing necrosis; preventing hypoxia |
| 09/04/2003 | US20030166563 Vpr proteins; lentiviral pol gene expression; human and simian immunodeficiency virus (HIV/SIV) vectors |
| 09/04/2003 | US20030166561 Such as preptin which is secreted by the pancreatic islet beta-cells for stimulating insulin secretion; immunoassay; kits |
| 09/04/2003 | US20030166560 Snail/mollusc polypeptides; anticonvulsant drug screening |
| 09/04/2003 | US20030166559 Comprises tumor necrosis factor antagonist activity for treatment of autoimmune conditions |
| 09/04/2003 | US20030166558 Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha-synuclein, or polyglutamine repeats for induction of an immune response thereto |
| 09/04/2003 | US20030166557 SEMA3B inhibits tumor growth and induces apoptosis in cancer cells |
| 09/04/2003 | US20030166556 Immunoregulator |
| 09/04/2003 | US20030166555 Methods and compositions for regulating memory consolidation |
| 09/04/2003 | US20030166553 Compositions for preventing and treating digestive organs diseases |
| 09/04/2003 | US20030166552 For removing viruses from samples (for protection against acquired immunodeficiency syndrome); contraceptives |
| 09/04/2003 | US20030166551 For inhibiting expression of adhesion molecules in vascular endothelial cells comprising adipose tissue-specific secretory factor |
| 09/04/2003 | US20030166550 Fibroblast growth factors and muteins thereof; for treatment of coronary artery disease, myocardial infarction |
| 09/04/2003 | US20030166549 Targeting peptides |
| 09/04/2003 | US20030166548 Synthetic milittin and related peptides derived from the sequence of human phospholipase A2-activating protein (PLAP), free from the contaminating phospholipase A2 (PLA2) and/or present when the peptides are purified from natural sources, |
| 09/04/2003 | US20030166547 Inducing angiogenesis in a tissue in need of angiogenesis, comprising providing the tissue in need of angiogenesis with an angiogenically effective amount of a recombinant c-fos induced growth factor/vascular endothelial growth factor D |
| 09/04/2003 | US20030166546 Uses of THANK, a TNF homologue that activates apoptosis |
| 09/04/2003 | US20030166545 Compounds and use thereof to modify transport across cell membranes |
| 09/04/2003 | US20030166544 Use of ADNP for the treatment of glaucomatous optic neuropathy |
| 09/04/2003 | US20030166543 Functional antagonists of hedgehog activity |
| 09/04/2003 | US20030166541 Novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. |
| 09/04/2003 | US20030166540 Polynucleotide encoding a novel human G-protein coupled receptor, HGPRBMY30 |
| 09/04/2003 | US20030166539 Compositions and methods of use for a bombesin peptide |
| 09/04/2003 | US20030166538 Isolated inflammation-related gene, the protein molecule encoded by the gene, and the use of the gene in diagnosis and treatment of inflammatory conditions. |
| 09/04/2003 | US20030166537 Use of a gial cell line-derived growth factor (GDNF) or a functionally active derivative or part thereof and/or an agonist which substitutes the functional activity of GDNF, and/ or a nucleic acid containing at least a nucleotide |
| 09/04/2003 | US20030166536 Expression product of DNA encoding human or hybrid human/ mammalian factor VIII, said DNA comprising DNA encoding a modified A2 domain, the DNA having one or more nucleotide substitutions resulting in a coding change at one or more of |
| 09/04/2003 | US20030166535 Preventing lesions of the upper alimentary canal, particularly oral aphthous or mucositis lesions. Intestinal trefoil peptides are administered in effective concentrations either alone or in combination with different therapeutic agents. |
| 09/04/2003 | US20030166534 Suppressing a class II MHC-restricted immune response in a mammal, or in mammalian cells, are described. The methods depend upon inhibiting invariant chain proteolysis by cathepsin S from class II MHC/invariant chain complexes, |
| 09/04/2003 | US20030166533 Genes for male accessory gland proteins in Drosophila melanogaster |
| 09/04/2003 | US20030166532 Annexin V, is used to prevent thrombosis without increasing hemorrhage. Annexin binds to phosphatidylserine on the outer surface of cell membranes, thereby preventing binding of the prothrombinase complex necessary for thrombus formation. |
| 09/04/2003 | US20030166531 Methods for modulating an immune response comprising contacting a cell with an agent that modulates the interaction between CTLA4 and PP2AA via modulating the lysine rich motif of CTLA4. The invention further provides methods |
| 09/04/2003 | US20030166529 Polypeptides and their uses |
| 09/04/2003 | US20030166528 Antifungal compound |
| 09/04/2003 | US20030166527 Granulocyte colony stimulating factor ("G-CSF") analog polypeptide compositions, related nucleic acids, expression constructs, host cells, and processes for recombinant production of the present G-CSF analogs. |
| 09/04/2003 | US20030166526 Novel gene (designated 158P1H4) and its encoded protein are described. While 158P1H4 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers including set forth in Table 1. Consequently, 158P1H4 |
| 09/04/2003 | US20030166525 FSH Formulation |
| 09/04/2003 | US20030166524 Therapeutic uses of IL-1 receptor antagonist |
| 09/04/2003 | US20030166523 Activating only the vascular endothelial growth factor receptor-3 has been created. The method comprises administration of a composition comprising a polypeptide to an animal wherein the composition has the ability to stimulate |
| 09/04/2003 | US20030166521 Inhibition of thrombosis by treatment with P-selectin antagonists |
| 09/04/2003 | US20030166515 Cyclosporins for the treatment of immune disorders |
| 09/04/2003 | US20030166514 Pharmaceutical composition comprising (a) the cyclic peptide compound of Formula 1 or Formula 2 as antigrowth agents or anticancer agents |
| 09/04/2003 | US20030166511 Cardioprotective composition comprising ceruloplasmin and uses thereof |
| 09/04/2003 | US20030166510 Methods and compositions for increasing skin remodeling |
| 09/04/2003 | US20030166509 Pharmaceutical compositions comprising nanoparticles containing a sustained release bioactive agent, method of making such compositions, and method of therapy using such compositions. |
| 09/04/2003 | US20030166508 Biologically active oral preparation that can be site-specific released in colon |
| 09/04/2003 | US20030166506 Method of producing n-[(2S)-sulfanyl-4-(1,5,5-trimethylhydantoinyl)butanoyl]-L-leucyl-L-tert-leucine N-methylamide and intermediate thereof |
| 09/04/2003 | US20030166505 Neo-tryptophan |
| 09/04/2003 | US20030166504 Therapeutic compositions and methods for treating viral infection |
| 09/04/2003 | US20030166502 Methods for selectively regulating survival and proliferation in a T cell by modulating the activity of certain amino acid motifs in the CD28 protein. |
| 09/04/2003 | US20030166300 Growth-related inflammatory and immune response protein |
| 09/04/2003 | US20030166289 Compositions and methods for regulating bacterial pathogenesis |
| 09/04/2003 | US20030166283 Drug screening a modulator as antitumor agents, antiproliferative agents, as promoter providing neuronal cell growth, wound healing, and cerebral injury healing; genetic engineering, receptor binding assay, gene expression |